drugset / Trial / NCT07302269
Study of the Safety, Tolerability, Pharmacokinetics of VV261 Tablets in Chinese Healthy Volunteers
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety, tolerability and pharmacokinetics characteristics of VV261 tablets in healthy adults.
Timeline
- Start
- 2026-01-04
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VV261 | Unknown | 5 mg | Oral |
| Subject | VV261 | Unknown | 20 mg | Oral |
| Subject | VV261 | Unknown | 50 mg | Oral |
| Subject | VV261 | Unknown | 100 mg | Oral |
| Subject | VV261 | Unknown | 150 mg | Oral |
| Subject | VV261 | Unknown | 300 mg | Oral |
| Subject | VV261 | Unknown | 500 mg | Oral |
| Subject | VV261 | Unknown | 750 mg | Oral |
| Subject | VV261 | Unknown | 1000 mg | Oral |
Indications
No indication recorded.